| US 7,368,448 B2 | ||
| 2-(arylalkoxy)-1-phenylethylamine derivatives as NK1 antagonist and serotonin reuptake inhibitors | ||
| Cathy Dantzman, Wilmington, Del. (US) | ||
| Assigned to AstraZeneca AB, Sodertalje (Sweden) | ||
| Appl. No. 10/599,824 PCT Filed Apr. 06, 2005, PCT No. PCT/SE2005/000499 § 371(c)(1), (2), (4) Date Oct. 11, 2006, PCT Pub. No. WO2005/100324, PCT Pub. Date Oct. 27, 2005. |
||
| Claims priority of application No. 0400968 (SE), filed on Apr. 14, 2004. | ||
| Prior Publication US 2007/0185127 A1, Aug. 09, 2007 | ||
| Int. Cl. A61K 31/497 (2006.01); C07D 241/04 (2006.01); C04D 295/00 (2006.01); C07C 211/00 (2006.01) | ||
| U.S. Cl. 514—252.12 [544/398; 564/428] | 10 Claims |
1. A compound according to structural diagram I:
 R1 and R2 are independently selected from C1-6alkyl or C1-6alkenyl, or together with the N to which they are bound, form a heterocycle containing 6, 7 or 8 atoms or such a heterocycle
substituted with moieties independently selected from hydrogen, halogen, C1-4alkyl, C1-4alkoxy, and C1-4alkyl substituted with 1, 2 or 3 halo or amino; wherein said amino is optionally substituted with C1-4alkyl, C1-4alkoxy or C1-4alkyl substituted with 1, 2, or 3 halo;
R4 is hydrogen;
n is 0, 1 or 2;
Ar1 is phenyl or phenyl substituted with moieties independently selected from hydrogen, halogen, —S—C1-4alkyl, C1-4alkyl, C1-4alkoxy and C1-4alkyl substituted with 1, 2 or 3 halo; and
Ar2 is naphthyl or tetralin, or naphthyl or tetralin substituted with moieties independently selected from hydrogen, halogen,
cyano, nitro, C1-4alkoxy, and C1-4alkyl substituted with 1, 2 or 3 halo moieties;
or an in vivo hydrolysable precursor or a pharmaceutically-acceptable salt thereof.
|